Crystal form of futibatinib, and preparation method therefor and use thereof
By developing the gallic acid cocrystal G2 of fubatinib, the stability and solubility issues of the existing crystal form were solved, achieving high stability and high solubility of the drug, thus ensuring the quality and bioavailability of the drug.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- QILU PHARMA CO LTD
- Filing Date
- 2025-12-09
- Publication Date
- 2026-06-18
AI Technical Summary
The existing fubatinib crystal form has problems with poor stability and low solubility, which affects the drug formulation dissolution and bioavailability, and is prone to quality changes during storage and transportation due to high hygroscopicity.
Multiple crystal forms and cocrystals of fubatinib have been developed, especially gallic acid cocrystal G2. Through screening, crystal forms with low hygroscopicity, high stability and improved solubility have been obtained, which are suitable for long-term storage of the formulation and improved bioavailability.
It improves the solubility and stability of fubatinib, reduces hygroscopicity, ensures the quality stability and bioavailability of the drug, and reduces quality changes of the drug during storage.
Smart Images
Figure CN2025140994_18062026_PF_FP_ABST